Advertisement

Andrology pp 399-418 | Cite as

Male Contribution to Contraception

  • E. Nieschlag
  • H. M. Behre
  • U. Engelmann
  • U. Schwarzer

Abstract

Making contraceptive methods available to men is one of the tasks of andrology. Such methods are necessary both to maintain stable populations in industrial nations, as well as to diminish population growth in developing countries (see Chap. 17).

Keywords

Patency Rate Contraceptive Method GnRH Agonist GnRH Antagonist Cyproterone Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akhtar FB, Marshall GR, Wickings EJ, Nieschlag E (1983a) Reversible induction of azoospermia in rhesus monkeys by constant infusion of a GnRH agonist using osmotic minipumps. J Clin Endocrinol Metab 56:534PubMedCrossRefGoogle Scholar
  2. Akhtar FB, Marshall GR, Nieschlag E (1983b) Testosterone supplementation attenuates the antifertility effects of an LHRH agonist in male monkeys. Int J Androl 6:461PubMedCrossRefGoogle Scholar
  3. Alan Guttmacher Institute (1999) Sharing responsibility: women, society and abortion worldwide. New YorkGoogle Scholar
  4. Alderman PM (1991) Complications in a series of 1224 vasectomies. J Fam Pract 33:579–584PubMedGoogle Scholar
  5. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM (1999) A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 20:407–414PubMedGoogle Scholar
  6. Anderson RA, Baird DT (1997) Progress towards a male pill. IPPF Med Bull 31:3–4Google Scholar
  7. April K, Köster R, Schreiner W (1993) Wie effektiv schützen Kondome vor einer HIV-Übertragung? Med Klinik 88:304–311Google Scholar
  8. Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ (1993) Comparison of a gonadotropin-releasing hormone antagonist plus testosterone (T) versus T alone as a potential male contraceptive regimen. J Clin Endocrinol Metab 77:427PubMedCrossRefGoogle Scholar
  9. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM (1996) Combined administration of levornorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 81:757–762PubMedCrossRefGoogle Scholar
  10. Behre HM, Nashan D, Hubert W, Nieschlag E (1992) Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 74:84PubMedCrossRefGoogle Scholar
  11. Behre HM, Böckers A, Schlingheider A, Nieschlag E (1994) Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men. Clin Endocrinol 40:241CrossRefGoogle Scholar
  12. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and non-responders. J Clin Endocrinol Metab 80:2394–2403PubMedCrossRefGoogle Scholar
  13. Belker AM, Thomas AJ, Fuchs EF, Konnak JW, Sharlip ID (1991) Result of 1,469 microsurgical vasectomy reversals by the vasovasostomy study group. J Urol 145:505–511PubMedGoogle Scholar
  14. Bonnar J, Flynn A, Freundl G, Kirkman R, Royston R, Snowden R (1999) Personal hormone monitoring for contraception. Br J Fam Plann 24:128–134PubMedGoogle Scholar
  15. Büchter D, von Eckardstein S, von Eckardstein A, Kamischke A, Simoni M, Behre HM, Nieschlag E (1999) Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab 84:1244–1249PubMedCrossRefGoogle Scholar
  16. Cooper TG, Yeung CH (1999) Recent biochemical approaches to post-testicular, epididymal contraception. Hum Reprod Update 5:141–152PubMedCrossRefGoogle Scholar
  17. Cos LR, Valvo JR, Davis RS, Cockett ATK (1983) Vasovasostomy: current state of the art. Urology 22:567–575PubMedCrossRefGoogle Scholar
  18. Deindl F (1990) Die Refertilisationssituation in der Bundesrepublik Deutschland, der Republik Österreich und der Schweiz — eine Dreiländerumfrage. Inaugural-Dissertation, Ruhr-Universität BochumGoogle Scholar
  19. Delanoe D, Fougeyrollas B, Meyer L, Thonneau P (1984) Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet 1:276PubMedCrossRefGoogle Scholar
  20. Derrick FC, Yarbbrough W, Agostino JD (1973) Vasovasostomy: results of questionnaire of members of the American Urological Association. J Urol 110:556–557PubMedGoogle Scholar
  21. Djerassi C, Leibo SP (1994) A new look at male contraception. Nature 370:11–12PubMedCrossRefGoogle Scholar
  22. De Vincenzi I for the European Study Group on Heterosexual Transmission of HIV (1994) A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N Engl J Med 331:341–346CrossRefGoogle Scholar
  23. Drake MJ, Mills IW, Cranston D (1999) On the chequered history of vasectomy. Br J Urol Int 84:475–481CrossRefGoogle Scholar
  24. Engelmann UH, Schramek P, Tomamichel G, Deindl F, Senge TH (1990) Vasectomy reversal in central Europe: results of a questionnaire of urologists in Austria, Germany and Switzerland. J Urol 143:64–67PubMedGoogle Scholar
  25. Farley TMM; Meirik O, Mehta S, Waites GMH (1993) The safety of vasectomy: recent concerns. Bull WHO 71:413–419PubMedGoogle Scholar
  26. Farnsworth NR, Waller DP (1982) Current status of plant products reported to inhibit sperm. Res Front Fertil Regul 2:1–16PubMedGoogle Scholar
  27. Feber KM, Ruiz HE (1999) Vasovasostomy: macroscopic approach and retrospective review. Techniques Urol 5:8–11Google Scholar
  28. Forste R, Tanfer K, Tedrow L (1995) Sterilization among currently married men in the United States, 1991. Fam Plann Perspect 27:100–107, 122PubMedCrossRefGoogle Scholar
  29. Frezieres RG, Walsh TL, Nelson AL, Clark VA, Coulson AH (1999) Evaluation of the efficacy of a polyurethane condom: results from a randomized, controlled clinical trial. Fam Plann Perspect 31:81–87PubMedCrossRefGoogle Scholar
  30. Giovanucci E, Tosteson TD, Speizer FE, Vessey MP, Colditz GA (1992) A long-term study of mortality in men who have undergone vasectomy. N Engl J Med 326:1392–1398CrossRefGoogle Scholar
  31. Giovanucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC (1993) A prospective cohort study of vasectomy and prostate cancer in US men. JAMA 269:873–877CrossRefGoogle Scholar
  32. Giwercman A, Skakkebaek NE (1986) The effect of salicylazosulphapyridine (sulphasalazine) on male fertility. A review. Int J Androl 9:38PubMedCrossRefGoogle Scholar
  33. Goebel P, Ortmann K, Blattner TH (1987) Vasektomie und Beziehungssituation — eine empirische Untersuchung an 156 Männern (Paaren). Zschr Psychosom Med 33:119–138Google Scholar
  34. Goldstein M, Shihua PhL, Matthews GJ (1998) Microsurgical Vasovasostomy: The microdot technique of precision suture placement. J Urol 159:188–190PubMedCrossRefGoogle Scholar
  35. Handelsman DJ, Conway AJ, Boylan LM (1992) Suppression of human spermatogenesis by testosterone implants. J Clin Endocrinol Metab 175:1326CrossRefGoogle Scholar
  36. Heidenreich A, Bonfig R, Wilbert DM, Strohmaier WL, Engelmann UH (1994) Risk factors for antisperm antibodies in infertile men. Am J Reprod Immunol 31:69–76PubMedCrossRefGoogle Scholar
  37. Hiersche HD, Hiersche F (1995) Die Sterilisation geistig Behinderter. Gynäkologe 28:452–458PubMedGoogle Scholar
  38. Isnardi L (1896) Die Behandlung der senilen Dysurie mit Durchschneidung und doppelseitiger Ligatur der vasa deferentia. Ther Wochenschr 111:25–36Google Scholar
  39. Jequier AM, Pryor JP (1998) Is vasectomy of long term benefits? Hum Reprod 13:1757–1760PubMedCrossRefGoogle Scholar
  40. John EM, Whittemore AS, Wu AH, Kolonel LN, Hislop TG, Howe GR, West DW, Hankin J, Dreon DM, Teh CZ (1995) Vasectomy and prostate cancer: results from a multiethnic casecontrol study. J Natl Cancer Inst 87:662–669PubMedCrossRefGoogle Scholar
  41. Kamischke A, Nieschlag E (2000) Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo controlled clinical trial for male contraception. Clin Endocrinol 53:43–52CrossRefGoogle Scholar
  42. Knuth UA, Mühlenstedt D (1991) Kinderwunschdauer, kontrazeptives Verhalten und Rate vorausgegangener Infertilitätsbehandlung. Geburtsh Frauenheilkd 51:1–7CrossRefGoogle Scholar
  43. Knuth UA, Behre HM, Beikien L, Bents H, Nieschlag E (1985) Clinical trial of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) for male fertility regulation. Fertil Steril 44:814PubMedGoogle Scholar
  44. Knuth UA, Yeung CH, Nieschlag E (1989) Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception. Fertil Steril 51:1011PubMedGoogle Scholar
  45. Kohli KL (1973) Motivational factors and socioeconomic characteristics of vasectomized males. J Biosoc Sci 5:169–177PubMedCrossRefGoogle Scholar
  46. Leonard JM, Paulsen CA (1978) Contraceptive development studies for males: oral and parenteral steroid hormone administation. In: Pantanelli DJ (ed) Hormonal control of male fertility. Department of Health, Education and Welfare. National Institutes of Health, Bethesda, pp 223Google Scholar
  47. Lesko SM, Louik C, Vezina R, Rosenberg L, Shapiro S (1999) Vasectomy and prostate cancer. J Urol 161:1848–1853PubMedCrossRefGoogle Scholar
  48. Liu X, Li S (1993) Vasal sterilization in China. Contraception 48:255–265PubMedCrossRefGoogle Scholar
  49. Martin CW, Anderson RA, Cheng L, Ho PC, van der Spuy Z, Smith KB, Glasier AF, Everington D, Baird DT (2000) Potential impact of hormonal male contraception: cross cultural implications for development of novel preparations. Hum Reprod 15:637–645PubMedCrossRefGoogle Scholar
  50. Meriggiola MC, Paulsen CA, Bremner WJ, Flamigni C (1996) A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab 81:3018–3023PubMedCrossRefGoogle Scholar
  51. Meriggiola MC, Bremner WJ, Constantino A, Pavani A, Capelli M, Flamigni C (1997) An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril 68:844–850PubMedCrossRefGoogle Scholar
  52. Mieusset R, Bujan L (1994) The potential of mild testicular heating as a safe, effective and reversible contraceptive method for men. Int J Androl 17:186–191PubMedCrossRefGoogle Scholar
  53. Miltsch B, Senn E (1999) Vasektomie: Präoperative Bedenken und postoperative Akzeptanz. Aktuel Urol 30:237–241CrossRefGoogle Scholar
  54. Moltz L, Römmler A, Post A, Schwartz U, Hammerstein J (1980) Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men. Contraception 21:393PubMedCrossRefGoogle Scholar
  55. National Institutes of Health (1993) Does vasectomy cause prostate cancer? JAMA 269:2620CrossRefGoogle Scholar
  56. Nieschlag E (1986) Reasons for abandoning immunization against FSH as an approach to male fertility regulation. In: Zatuchni GI, Goldsmith A, Spieler JM, Sciarra JJ (eds) Male contraception: advances and future prospects. Harper and Row, Philadelphia, pp 395–400Google Scholar
  57. Nieschlag E (1987) Vasektomie — pro und contra. Dtsch Med Wochenschr 112:1107–1109PubMedCrossRefGoogle Scholar
  58. Nieschlag E, Behre HM, Weinbauer GF (1992) Hormonal male contraception: A real chance? In: Nieschlag E, Habenicht UF (eds) Spermatogenesis — fertilitzation — contraception. Molecular, cellular and endocrine events in male reproduction. Springer, Berlin Heidelberg New York, pp 477–501CrossRefGoogle Scholar
  59. Nieschlag E, Behre HM (1996) Hormonal male contraception: Suppression of spermatogenesis with GnRH antagonists and testosterone. In: Filicori M (ed) Treatment with GnRH analogs: controversies and perspectives. Parthenon, London, pp 243–248Google Scholar
  60. Nieschlag E, Hoogen H, Bölk M, Schuster H, Wickings EJ (1978) Clinical trial with testosterone undecanoate for male fertility control. Contraception 18: 607PubMedCrossRefGoogle Scholar
  61. Nirapathpongporn A, Huber DH, Krieger JN (1990) No-scalpel vasectomy at the King’s birthday vasectomy festival. Lancet 335:894–895PubMedCrossRefGoogle Scholar
  62. Ochsner AJ (1899) Surgical treatment of habitual criminals. JAMA 33:867–868CrossRefGoogle Scholar
  63. O’Connor VJ (1948) Anastomosis of the vas deferens after purposeful division for sterility. J Urol 59:229–233Google Scholar
  64. Pavlou SN, Herodotou D, Curtain M, Minaretzis D (1994) Complete suppression of spermatogenesis by co-administration of a GnRH antagonist plus a physiologic dose of testosterone. 76th Meeting Endocrine Society, Abstract 1324Google Scholar
  65. Prasad MR, Diczfalusy NE (1982) Gossypol. Int J Androl [Suppl] 28:53CrossRefGoogle Scholar
  66. Randall PE, Marcuson RW (1985) Absence from work following vasectomy. J Soc Occup Med 35:77–78PubMedCrossRefGoogle Scholar
  67. Reissmann T, Engel J, Kutscher B, Bernd M, Hilgard P, Peukert M, Szelenyi I, Reichert S, Gonzales-Barcena D, Nieschlag E, Comary-Schally AM, Schally AV (1994) Cetrorelix. Drugs Future 19:228–237Google Scholar
  68. Reynolds RD (1994) Vas deferens occlusion during no-scalpel vasectomy. J Fam Pract 39:577–582PubMedGoogle Scholar
  69. Rizvi SAH, Naqvi SAA, Hussain Z (1995) Ethical issues in male sterilization in developing countries. Br J Urol 76:103–105PubMedCrossRefGoogle Scholar
  70. Rosenberg MJ, Waugh MS (1997) Latex condom breakage and slippage in a controlled clinical trial. Contraception 56:17–21PubMedCrossRefGoogle Scholar
  71. Ross JA, Huber DH (1983) Acceptance and prevalence of vasectomy in developing countries. Stud Fam Plan 14:67–73CrossRefGoogle Scholar
  72. Roth S, Hertle L (1994) Verursacht die Sterilisations-Vasekto-mie ein Prostatakarzinom? Dt Ärztebl 91:409–410Google Scholar
  73. Rothman I, Berger RE, Cummings P, Jessen J, Muller ChH, Chapman W (1997) Randomized clinical trial of an absorbable stent for vasectomy reversal. J Urol 157:1697–1700PubMedCrossRefGoogle Scholar
  74. Russell-Brown P, Piedrahita C, Foldesy R, Steiner M, Townsend J (1992) Comparison of condom breakage during human use with performance in laboratory testing. Contraception 45:429–437PubMedCrossRefGoogle Scholar
  75. Sanches FA, Brache V, Leon P, Faundes A (1979) Inhibition of spermatogenesis with monthly injections of medroxyprogesterone acetate and low dose testosterone enanthate. Int J Androl 2:136CrossRefGoogle Scholar
  76. Schearer SB (1978) The use of progestins and androgens as a male contraceptive. Int J Androl [Suppl] 2:680CrossRefGoogle Scholar
  77. Schirren C (1983) Erfahrungen mit der Vasektomie. Urologe A 22:29–34PubMedGoogle Scholar
  78. Schürmeyer T, Knuth UA, Freischem CW, Sandow J, Akhtar FB, Nieschlag E (1984) Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion. J Clin Endocrinol Metab 59:19PubMedCrossRefGoogle Scholar
  79. Segal SJ (1985) Gossypol: a potential contraceptive for men. Plenum, New YorkGoogle Scholar
  80. Sharp HC (1902) The severing of the vasa deferentia and its relation to the neuropsychopathic constitution. NY Med J 75:411–414Google Scholar
  81. Silber SJ (1977) Perfect anatomical reconstruction of vas deferens with a new microscopic surgical technique. Fertil Steril 28:72–77PubMedGoogle Scholar
  82. Smith GL, Taylor GP, Smith KF (1985) Comparative risks and costs of male and female sterilization. Am J Pub Health 75:370–374CrossRefGoogle Scholar
  83. Soufir J-C, Jouannet P, Marson J, Soumah A (1983) Reversible inhibition of sperm production and gonadotropin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment. Acta Endocrinol 102:625PubMedGoogle Scholar
  84. Steiner M, Foldesy R, Cole D, Carter E (1992) Study to determine the correlation between condom breakage in human use and laboratory test results. Contraception 46:279–288PubMedCrossRefGoogle Scholar
  85. Trussell J, Hatcher RA, Cates W, Stewart FH, Kost K (1990) Contraceptive failure in the United States: an update. Stud Fam Plan 21:51–54CrossRefGoogle Scholar
  86. Vaughn R (1979) Behavioral response to vasectomy. Arch Gen Psychiatry 36:815–821PubMedCrossRefGoogle Scholar
  87. Waites GMH (1993) Male fertility regulation: the challenges for the year 2000. Br Med Bull 49:210PubMedGoogle Scholar
  88. Waites GMH, Wang C, Griffin PD (1998) Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. Int J Androl 21:8–12PubMedCrossRefGoogle Scholar
  89. Wang C, Yeung KK (1980) Use of low-dosage oral cyproterone acetate as a male contraceptive. Contraception 21:245PubMedCrossRefGoogle Scholar
  90. Wang C, McDonald V, Leung A, Superlano L, Berman N, Hull L, Swerdloff RS (1997) Effect of increased scrotal temperature on sperm production in normal men. Fertil Steril 68:334–339PubMedCrossRefGoogle Scholar
  91. Weidner W, Weißbach L (1992) Freiwillige Vasektomie in der Familienplanung — Gedanken zur Nutzen-Risiko-Analyse. Aktuel Urol 23:328–331CrossRefGoogle Scholar
  92. Weinbauer GF, Göckeler E, Nieschlag E (1988) Testosterone prevents complete suppression of spermatogenesis in the gonadotropin-releasing hormone (GnRH) antagonist-treated nun-human primate (Macaca fascicularis). J Clin Endocrinol Metab 67:284PubMedCrossRefGoogle Scholar
  93. Weller SC (1993) A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Soc Sci Med 36:1635–1644PubMedCrossRefGoogle Scholar
  94. WHO (1972–1998) Special programme of research, development and research training in human reproduction. Annual and biannual reports. WHO, GenfGoogle Scholar
  95. WHO Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955–959CrossRefGoogle Scholar
  96. WHO Task Force on Methods for the Regulation of Male Fertility (1993) Comparison of two androgens plus depot-me-droxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril 60:1062Google Scholar
  97. WHO Task Force on Methods for the Regulation of Male Fertility (1995) Rate of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies. Int J Androl 18:157–165CrossRefGoogle Scholar
  98. WHO Task Force on Methods for the Regulation of Male Fertility (1996) Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65:821–829Google Scholar
  99. WHO/HRP (1997) Preclinical and clinical requirements for approval to market non-latex condoms. WHO, GenfGoogle Scholar
  100. Wicklund R, Alexander NJ (1979) Vasovasostomy: evaluation of success. Urology 13:532–534PubMedCrossRefGoogle Scholar
  101. Wolfers D, Wolfers H (1974) Vasectomy and vasectomania. Mayflower Books, LondonGoogle Scholar
  102. Wright N, Johnson B, Wiggins P, Vessey M (1977) The use of sterilisation as a method of birth control among participants in the Oxford/Family Planning Association Contraceptive Study. Fertil Contracept 1:41–44Google Scholar
  103. Wu FC, Balasubramanian R, Mulders TM, Coelingh-Benningk HJ (1999) Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J Clin Endocrinol Metab 84:112–122PubMedCrossRefGoogle Scholar
  104. Yu Z-H, Chan HC (1998) Gossypol as a male antifertility agent — why studies should have been continued. Int J Androl 21:2–7PubMedCrossRefGoogle Scholar
  105. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ (1999) A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab 84:3642–3647PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • E. Nieschlag
  • H. M. Behre
  • U. Engelmann
  • U. Schwarzer

There are no affiliations available

Personalised recommendations